• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

c-MYC 基因表达在血液系统恶性肿瘤中的诊断和预后价值。

Diagnostic and prognostic value of c-MYC gene expression in hematological malignancies.

机构信息

Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science, University of Calabar, Nigeria.

Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, Arthur Jarvis University, Akpabuyo, Nigeria.

出版信息

Afr Health Sci. 2023 Jun;23(2):265-273. doi: 10.4314/ahs.v23i2.30.

DOI:10.4314/ahs.v23i2.30
PMID:38223598
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10782349/
Abstract

INTRODUCTION

c-MYC plays vital role in regulation of cell proliferation and has been associated with tumorigenesis. This study is aimed at assessing diagnostic and prognostic value of plasma c-MYC expression to aid in early diagnosis and prognosis of hematological malignancies.

METHODS

Plasma c-MYC expression was determined by quantitative real time PCR using EVA Green chemistry and cluster of differentiation markers performed via immunocytochemistry.

RESULT

Plasma c-MYC was higher in subject with hematological malignancies (8.8 ± 1.1) when compared with apparently healthy controls (4.5 ± 0.5). A screening cut-off c-MYC ratio value of 9.42 with sensitivity and specificity of 65.5% and 100% respectively were obtained using receiver operator characteristic curve analysis. Plasma c-MYC was found to have no prognostic value using Kaplan-Meier analysis.

CONCLUSION

Plasma c-MYC ratio showed promising screening/diagnostic value for hematological malignancies.

摘要

简介

c-MYC 在细胞增殖的调控中起着至关重要的作用，并且与肿瘤发生有关。本研究旨在评估血浆 c-MYC 表达的诊断和预后价值，以帮助早期诊断和预测血液系统恶性肿瘤。

方法

使用 Eva Green 化学和免疫细胞化学进行的定量实时 PCR 测定了血浆 c-MYC 的表达，并通过免疫细胞化学测定了分化标记物。

结果

与明显健康的对照组（4.5 ± 0.5）相比，患有血液系统恶性肿瘤的患者（8.8 ± 1.1）的血浆 c-MYC 更高。使用接收器操作特征曲线分析获得了筛选截止值 c-MYC 比值为 9.42，灵敏度和特异性分别为 65.5%和 100%。通过 Kaplan-Meier 分析发现，血浆 c-MYC 无预后价值。

结论

血浆 c-MYC 比值显示出对血液系统恶性肿瘤具有有前途的筛查/诊断价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/9700738557db/AFHS2302-0265Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/899bf7510638/AFHS2302-0265Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/aae0d5ca92f5/AFHS2302-0265Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/6bafaa17b0e9/AFHS2302-0265Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/8d6948f87245/AFHS2302-0265Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/9700738557db/AFHS2302-0265Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/899bf7510638/AFHS2302-0265Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/aae0d5ca92f5/AFHS2302-0265Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/6bafaa17b0e9/AFHS2302-0265Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/8d6948f87245/AFHS2302-0265Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9a4/10782349/9700738557db/AFHS2302-0265Fig5.jpg

相似文献

1
Diagnostic and prognostic value of c-MYC gene expression in hematological malignancies.c-MYC 基因表达在血液系统恶性肿瘤中的诊断和预后价值。
Afr Health Sci. 2023 Jun;23(2):265-273. doi: 10.4314/ahs.v23i2.30.
2
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.MYC：一种具有预后和治疗意义的多效癌基因，在血液恶性肿瘤中。
J Hematol Oncol. 2021 Aug 9;14(1):121. doi: 10.1186/s13045-021-01111-4.
3
Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.血液系统恶性肿瘤中MYC异常表达的发病机制及治疗靶点
Br J Haematol. 2017 Dec;179(5):724-738. doi: 10.1111/bjh.14917. Epub 2017 Nov 24.
4
Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies.TDAG8 在血液系统恶性肿瘤中的肿瘤抑制功能与上下文相关。
J Transl Med. 2017 Oct 10;15(1):204. doi: 10.1186/s12967-017-1305-6.
5
MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.受MicroRNA-21调控异常的MicroRNA-184通过靶向细胞周期蛋白依赖性激酶25A（CDC25A）和c-Myc促进非小细胞肺癌的肿瘤恶性进展及不良预后。
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1532-9. doi: 10.1245/s10434-015-4595-z. Epub 2015 May 20.
6
Plasma level manifesting as an indicator in progression of breast cancer.血浆水平作为乳腺癌进展的指标表现出来。
Biomark Med. 2019 Aug;13(11):917-929. doi: 10.2217/bmm-2019-0073. Epub 2019 May 30.
7
Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection.c-Myc 蛋白低表达预示着肝癌患者手术后预后不良。
BMC Cancer. 2018 Apr 24;18(1):460. doi: 10.1186/s12885-018-4379-5.
8
Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.关于接受R-CHOP或R-CHOEP治疗的高危弥漫性大B细胞淋巴瘤年轻患者的真实世界数据——MYC、BCL2和BCL6作为预后生物标志物
PLoS One. 2017 Oct 31;12(10):e0186983. doi: 10.1371/journal.pone.0186983. eCollection 2017.
9
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.CIP2A在胃癌中的MYC依赖性调控及预后作用
J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. doi: 10.1093/jnci/djp103. Epub 2009 May 26.
10
Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression.远上游元件结合蛋白1是一种预后生物标志物，可促进鼻咽癌进展。
Cell Death Dis. 2015 Oct 15;6(10):e1920. doi: 10.1038/cddis.2015.258.

引用本文的文献

1
Editor's choice: Covid-19 and HIV are still very much with us.编辑推荐：新冠病毒和艾滋病毒仍与我们紧密相伴。
Afr Health Sci. 2023 Jun;23(2):i-v. doi: 10.4314/ahs.v23i2.1.

本文引用的文献

1
Causes of morbidity and mortality among patients admitted in a tertiary hospital in southern Nigeria: A 6 year evaluation.尼日利亚南部一家三级医院住院患者的发病率和死亡率原因：6 年评估。
PLoS One. 2020 Aug 25;15(8):e0237313. doi: 10.1371/journal.pone.0237313. eCollection 2020.
2
Blood donors deferral prevalence and causes in a tertiary health care hospital, southern Nigeria.尼日利亚南部一家三级保健医院的献血者暂缓献血率及原因。
BMC Health Serv Res. 2019 Jul 22;19(1):510. doi: 10.1186/s12913-019-4352-2.
3
Plasma level manifesting as an indicator in progression of breast cancer.
血浆水平作为乳腺癌进展的指标表现出来。
Biomark Med. 2019 Aug;13(11):917-929. doi: 10.2217/bmm-2019-0073. Epub 2019 May 30.
4
The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects.c-MYC在B细胞淋巴瘤中的作用：诊断与分子层面
Genes (Basel). 2017 Apr 5;8(4):116. doi: 10.3390/genes8040116.
5
Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.MYC蛋白表达在中枢神经系统弥漫性大B细胞淋巴瘤中的预后影响：与MYC重排及MYC mRNA表达的比较
Mod Pathol. 2017 Jan;30(1):4-14. doi: 10.1038/modpathol.2016.56. Epub 2016 Sep 30.
6
The c-MYC protooncogene expression in cholesteatoma.胆脂瘤中c-MYC原癌基因的表达
Biomed Res Int. 2014;2014:639896. doi: 10.1155/2014/639896. Epub 2014 Feb 10.
7
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.在接受免疫化疗的弥漫性大 B 细胞淋巴瘤患者中，MYC 蛋白表达和基因改变具有预后影响。
Haematologica. 2013 Oct;98(10):1554-62. doi: 10.3324/haematol.2013.086173. Epub 2013 May 28.
8
Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1.内部核糖体进入导致多发性骨髓瘤中 c-myc 表达上调，这是由于与 PTB-1 和 YB-1 的相互作用增加和表达增加所致。
Oncogene. 2010 May 13;29(19):2884-91. doi: 10.1038/onc.2010.31. Epub 2010 Mar 1.
9
c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.c-Myc 过表达促进伯基特淋巴瘤中生发中心样程序。
Oncogene. 2010 Feb 11;29(6):888-97. doi: 10.1038/onc.2009.377. Epub 2009 Nov 2.
10
Prevalence of c-myc expression in breast lesions associated with microcalcifications detected by routine mammography.通过常规乳腺X线摄影检测到的与微钙化相关的乳腺病变中c-myc表达的患病率。
Sao Paulo Med J. 2009 May;127(2):66-70. doi: 10.1590/s1516-31802009000200003.